Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
Pulse Biosciences (Nasdaq: PLSE) has appointed Paul A. LaViolette to its Board of Directors as Co-Chairman alongside Robert W. Duggan. LaViolette brings 40 years of medical technology development, operating, and leadership expertise to the company, which specializes in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. His extensive experience includes roles as Chief Operating Officer at Boston Scientific and current positions as Managing Partner at SV Health Investors and director for Edwards Lifesciences. LaViolette's appointment is expected to provide valuable insights and expertise to help Pulse Biosciences develop transformational treatments and maximize the potential of its proprietary technology across various therapeutic categories.
Pulse Biosciences (Nasdaq: PLSE) ha nominato Paul A. LaViolette nel suo Consiglio di Amministrazione come Co-Presidente insieme a Robert W. Duggan. LaViolette porta con sé 40 anni di esperienza nello sviluppo, nella gestione e nella leadership nel settore della tecnologia medica all'interno dell'azienda, che si specializza nella tecnologia Nanosecond Pulsed Field Ablation™ (nsPFA™). La sua vasta esperienza include ruoli come Direttore Operativo presso Boston Scientific e attuali posizioni come Managing Partner in SV Health Investors e direttore di Edwards Lifesciences. La nomina di LaViolette è attesa per fornire preziose intuizioni e competenze che aiuteranno Pulse Biosciences a sviluppare trattamenti trasformativi e massimizzare il potenziale della sua tecnologia proprietaria in diverse categorie terapeutiche.
Pulse Biosciences (Nasdaq: PLSE) ha nombrado a Paul A. LaViolette en su Junta Directiva como Co-Presidente junto a Robert W. Duggan. LaViolette aporta 40 años de experiencia en desarrollo de tecnología médica, operación y liderazgo a la empresa, que se especializa en la tecnología de Ablación por Campo Pulsado de Nanosegundos™ (nsPFA™). Su amplia experiencia incluye roles como Director de Operaciones en Boston Scientific y posiciones actuales como Socio Gerente en SV Health Investors y director de Edwards Lifesciences. Se espera que la designación de LaViolette proporcione valiosos conocimientos y experiencia para ayudar a Pulse Biosciences a desarrollar tratamientos transformadores y maximizar el potencial de su tecnología propietaria en diversas categorías terapéuticas.
Pulse Biosciences (Nasdaq: PLSE)는 Paul A. LaViolette를 Robert W. Duggan과 함께 공동 의장으로 이사회에 임명했습니다. LaViolette는 이 회사에 의료 기술 개발, 운영 및 리더십 분야에서 40년의 전문 지식을 제공합니다. Pulse Biosciences는 나노초 펄스 필드 소작(Nanosecond Pulsed Field Ablation™, nsPFA™) 기술을 전문으로 합니다. 그의 광범위한 경험에는 Boston Scientific의 최고 운영 책임자 직위와 SV Health Investors의 관리 파트너, 및 Edwards Lifesciences의 이사직이 포함됩니다. LaViolette의 임명이 Pulse Biosciences가 혁신적인 치료법을 개발하고 자사의 기술의 잠재력을 다양한 치료 범주에서 극대화하는 데 중요한 통찰력과 전문 지식을 제공할 것으로 기대됩니다.
Pulse Biosciences (Nasdaq: PLSE) a nommé Paul A. LaViolette à son Conseil d'Administration en tant que Co-Président aux côtés de Robert W. Duggan. LaViolette apporte à l'entreprise 40 ans d'expertise en développement de technologies médicales, en opérations et en leadership, spécialisée dans la technologie d'Ablation par Champ Pulsé Nanoseconde™ (nsPFA™). Son expérience étendue inclut des rôles en tant que Directeur des Opérations chez Boston Scientific et des postes actuels en tant qu'Associé Gérant chez SV Health Investors et directeur chez Edwards Lifesciences. La nomination de LaViolette devrait fournir des connaissances précieuses et une expertise pour aider Pulse Biosciences à développer des traitements transformateurs et à maximiser le potentiel de sa technologie propriétaire dans diverses catégories thérapeutiques.
Pulse Biosciences (Nasdaq: PLSE) hat Paul A. LaViolette in seinen Vorstand als Co-Vorsitzenden zusammen mit Robert W. Duggan berufen. LaViolette bringt 40 Jahre Erfahrung in der Entwicklung, im Betrieb und in der Führung von Medizintechnologien in das Unternehmen ein, das sich auf die Technologie der Nanosekunden gepulsten Feldablation™ (nsPFA™) spezialisiert hat. Zu seiner umfangreichen Erfahrung gehören Positionen als Chief Operating Officer bei Boston Scientific sowie aktuelle Tätigkeiten als Managing Partner bei SV Health Investors und Direktor bei Edwards Lifesciences. LaViolette's Ernennung wird voraussichtlich wertvolle Einblicke und Expertise bieten, um Pulse Biosciences bei der Entwicklung transformierender Behandlungen zu unterstützen und das Potenzial seiner proprietären Technologie in verschiedenen therapeutischen Kategorien zu maximieren.
- Appointment of Paul LaViolette, an industry veteran with 40 years of experience, to the Board of Directors
- LaViolette's extensive experience in scaling global cardiology franchises and driving innovative technology adoption
- Potential for LaViolette's insights to help develop valuable therapeutic treatments and maximize the company's technology potential
- None.
Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
“We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical technology space for decades,” stated Pulse Biosciences’ Co-Chairman Robert W. Duggan. “He adds a wealth of relevant expertise to our Board based on his experience successfully scaling some of the largest global cardiology franchises through driving innovative technology adoption. We are excited to work with him and benefit from his valuable insights for the years to come.”
Paul LaViolette has significant experience as a large-scale operator at healthcare corporations, as well as an advisor to a diverse group of innovative medical technology startups as a venture investor and board member. He is currently Managing Partner at SV Health Investors, investing in portfolio companies for its Medtech Convergence Fund. Before his investing career, he served in various executive capacities at Boston Scientific Corporation for 15 years, including as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International. Prior to Boston Scientific, he also held general management and commercial leadership positions at CR Bard and various marketing roles at Kendall (Medtronic).
Mr. LaViolette has experience in both chairman and director capacities for numerous private and public medical technology companies. He is currently a director for Edwards Lifesciences, Chairman of the Innovation Advisory Board at Mass General Brigham, and is a director or Chairman on multiple private medical device company boards. Mr. LaViolette received his bachelor’s degree in psychology from
“I am honored to join the Board at Pulse Biosciences. The Company’s highly differentiated and proprietary technology, and potential to advance the clinical standard of care across numerous therapeutic categories, represents a truly unique opportunity. I am thrilled to be involved with this next-generation energy source and to help the management team methodically develop the most valuable therapeutic treatments to maximize its potential for patients. I am excited to help the team build transformational treatments for unmet patient needs,” said Paul LaViolette, incoming Co-Chairman of Pulse Biosciences’ Board of Directors.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812274932/en/
Investors:
Pulse Biosciences, Inc.
Burke T. Barrett, President and CEO
IR@pulsebiosciences.com
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
FAQ
Who is Paul LaViolette and what is his new role at Pulse Biosciences (PLSE)?
What is Paul LaViolette's background in the medical technology industry?
How might Paul LaViolette's appointment impact Pulse Biosciences (PLSE)?
What is Pulse Biosciences' (PLSE) main technology focus?
